Prof. Dr. Wolfgang Wick, MD
Phone: +49 (0) 6221 56-7075

Prof. Dr. Ricarda Diem

Prof. Dr. Frank Winkler



Improving neurooncology...


by passionate clinics and great science.



Our group/department has:

  • demonstrated in joint projects with the Neuroradiology group that antiangiogenic therapies do not promote diffuse infiltration at clinical significance (Wick A et al. Ann Neurol 2011; Radbruch Neuro Oncol 2012; Lutz J Magn Reson Imaging 2013; Deistung Plos One 2013; Nowosielski, Wiestler B Neurology in press)
  • provided evidence that NDRG1 is a central and druggable molecular hub integrating diverse therapy-induced microenvironmental factors to promote resistance towards alkylating chemotherapy and suggest that NDRG1-mediated chemoprotection is achieved via binding and stabilizing methyltransferases, such as MGMT (Blaes J Neurooncol 2014; Weiler Proc Natl Acad Sci 2014) (Fig. 2)
  • shown together with the Neuropathology group that molecular biomarkers enter clinical practice in anaplastic gliomas (Wick Neurology 2013; Koelsche Acta Neuropathol 2013; Wiestler B Acta Neuropathol 2013) (Fig. 3)
  • defined a new standard of practice for elderly patients with malignant astrocytomas and introduced molecular markers to separate older and younger patients with brain tumors (Wick The Lancet Oncol 2012; Weller…Wick The Lancet Oncol in press; Wiestler B Neuro Oncol 2013) (Fig. 3)
  • build together with the partners from the Heidelberg campus international brain tumor trial consortia with inbuilt standard molecular and imaging protocols (EORTC trial 26082 – temosirolimus/phase II; EORTC trial 26101 – bevacizumab/phase II/III; S039 – Enzastaurin, Wick Neuro Oncol 2013 and APG101 Wick ECCO 2013)
  • partnered the GAPVAC EU consortium for personalized peptide-based active immunotherapy for patients with newly diagnosed glioblastoma as the lead clinical site.

2010 – 2013

  • Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab Plus Radiotherapy/Temozolomide for Newly Diagnosed Glioblastoma. New Engl J Med in press
  • Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper M, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M. Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol 2012; 13(7):707-715.
  • Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013; 126(3):443-51.
  • Weiler M, Pfenning PN, Thiepold AL, Blaes J, Jestaedt L, Gronych J, Dittmann LM, Berger B, Jugold M, Kosch M, Combs SE, von Deimling A, Weller M, Bendszus M, Platten M, Wick W. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene 2013; 32(9):1099-109
  • Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M, Wick W. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
    Clin Cancer Res 2012; 18(1):105-17.
  • DFG - SFB 938, K: Control of CNS Immunity by Tryptophan Metabolism. 2011-2014
  • DFG/Land BadenWürttemberg/DKFZ – §91b: Multiphotone Mikroscope. 2011
    German Cancer Aid 110624: Molecular classification of anaplastic gliomas in the NOA-04 Trial
  • BMBF – National Genome Research Network (Brain Tumor Network): TP 6a, TP 10 and TP14; 2010-2012